Akers Biosciences and Premas Biotech Announce Successful Completion of Vaccine Prototype & Obtained First Images of VLP (GlobeNewswire, Akers Biosciences Inc.) - May 14, 2020 - "Thorofare, New Jersey, May 14, 2020 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc (the "Company") (NASDAQ: AKER), a developer of rapid health information technologies, today announced that Premas Biotech, its partner in the development of a vaccine candidate that is seeking to address the COVID-19 pandemic, has successfully completed its vaccine prototype. The vaccine candidate is based on the three COVID-19 proteins; Spike, Envelope and Membrane."
New trial • Preclinical • Infectious Disease • Novel Coronavirus Disease
|